OPEN LABEL EXTENDED USE DELAVIRDINE MESYLATE FOR HIV+ PATIENTS

甲磺酸地拉韦啶开放标签延长用于 HIV 患者

• 批准号: 6281694
• 负责人: PHILIP C JOHNSON
• 金额: $ 1.36万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6281694
• 关键词: 2'3' dideoxycytidine; 2'3' dideoxyinosine; AIDS therapy; HIV infections; clinical research; combination chemotherapy; delavirdine; drug screening /evaluation; helper T lymphocyte; human immunodeficiency virus 1; human subject; human therapy evaluation; lamivudine; polymerase chain reaction; stavudine; virus RNA; zidovudine

The aim of the protocol is to evaluate the safety and tolerance of long- term triple therapy combination of delavirdine mesylate, AZT, and either ddI or DDC, D4T, or 3TC in HIV positive individuals who were participants in other delavirdine mesylate protocols. The study will also evaluate the efficacy of the triple therapy based on changes in CD4 counts, plasma HIV-1 RNA by PCR, and on time to disease progression or death. Patients will be seen monthly for two years. This study was closed in September, 1997.

该方案的目的是评估长时间的安全性和耐受性